interleukin-8 has been researched along with Chest-Pain* in 2 studies
2 other study(ies) available for interleukin-8 and Chest-Pain
Article | Year |
---|---|
Inflammatory cytokines provide limited early prognostic information in emergency department patients with suspected myocardial ischemia.
The aim of this study was to assess the early prognostic value of the inflammatory cytokines interleukin 6, interleukin 8, and tumor necrosis factor alpha in a cohort of emergency department (ED) patients with chest pain who have suspected myocardial ischemia.. One hundred eighteen patients with chest pain presenting to 2 urban EDs were studied. Interleukin 6, interleukin 8, and tumor necrosis factor alpha levels were assayed at presentation. The end point was the occurrence of a serious cardiac event (death, nonfatal acute myocardial infarction, myocardial revascularization, or readmission with an acute coronary syndrome) during the index admission or subsequent 3 months.. Mean levels of all 3 cytokines were higher among patients experiencing a serious cardiac event, with the greatest differences observed in levels of interleukin 6 (mean 2.5 pg/mL [95% confidence interval (CI) 1.2 to 3.7 pg/mL] versus mean 9.8 pg/mL [95% CI 2.4 to 17.2 pg/mL]). Interleukin 6 had a sensitivity of 35% (95% CI 20% to 54%), a specificity of 86% (95% CI 76% to 92%), and an overall prognostic accuracy of 71% (95% CI 63% to 79%) for predicting serious cardiac events. However, logistic regression analysis revealed that the only independent predictor of an adverse outcome was an ECG suggestive of ischemia at presentation.. Among patients presenting to the ED with suspected myocardial ischemia, higher levels of inflammatory cytokines are associated with an increased risk of a serious cardiac event during the subsequent 3 months. There is, however, considerable overlap in levels among patients who do and do not have a serious cardiac event, limiting their utility as predictors of outcome in individual patients. Topics: Chest Pain; Emergency Service, Hospital; Female; Hospitals, Urban; Humans; Interleukin-6; Interleukin-8; Logistic Models; Male; Middle Aged; Myocardial Ischemia; Predictive Value of Tests; Prognosis; Prospective Studies; ROC Curve; Sensitivity and Specificity; Tumor Necrosis Factor-alpha | 2003 |
Elevated serum and bronchoalveolar lavage fluid levels of interleukin 8 and granulocyte colony-stimulating factor associated with the acute chest syndrome in patients with sickle cell disease.
The role of cytokines in the development of acute chest syndrome (ACS) in patients with sickle cell disease (SCD) was studied. Serum interleukin 8 (IL-8) levels were elevated in 14 episodes and undetectable in six out of 20 episodes of ACS in 19 patients with SCD. In contrast, IL-8 levels were undetectable in the sera of 29 control patients with SCD studied during routine clinic visits or hospitalization for vaso-occlusive crises. The differences in mean IL-8 levels and the proportion of patients with detectable levels between the two groups were highly significant (P < 0.0001 and 0.04 respectively). The mean IL-8 level in bronchial fluid samples from children with ACS was also significantly higher than that in sickle cell patients undergoing elective surgery (5500 +/- 1400 pg/ml vs. 1900 +/- 470 pg/ml, P = 0.03). Granulocyte colony-stimulating factor (G-CSF) (2000 +/- 1700 pg/ml) was present in five out of six samples of bronchial fluid, but not serum, from children with ACS. All but one of the patients with ACS studied were negative for the Duffy red cell antigen, which is a receptor that binds and inactivates IL-8 and other chemokines. These findings suggest that IL-8 and G-CSF may play a role in the development of the ACS and the complications associated with it. Topics: Acute Disease; Adolescent; Adult; Bronchoalveolar Lavage Fluid; Case-Control Studies; Chest Pain; Child; Child, Preschool; Cytokines; Duffy Blood-Group System; Female; Granulocyte Colony-Stimulating Factor; Humans; Interleukin-8; Male; Pleural Effusion; Polymerase Chain Reaction; RNA, Messenger; Sickle Cell Trait; Syndrome | 2000 |